Patents by Inventor Ravindra R. Yarragunta

Ravindra R. Yarragunta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8404731
    Abstract: The present invention provides imidazole derivatives of Formula (I-IV), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I-IV), and their use in treating human or animal disorders. The compounds of the invention inhibit protein tyrosine phosphatase 1B and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: March 26, 2013
    Assignee: TransTech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Dharma R. Polisetti, Govindan Subramanian, James C. Quada, Ravindra R. Yarragunta, Robert C. Andrews, Rongyuan Xie
  • Publication number: 20120196906
    Abstract: The present invention provides imidazole derivatives of Formula (I-IV), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I-IV), and their use in treating human or animal disorders. The compounds of the invention inhibit protein tyrosine phosphatase 1B and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.
    Type: Application
    Filed: March 6, 2012
    Publication date: August 2, 2012
    Applicant: TransTech Pharma, Inc.
    Inventors: Adnan M.M. Mjalli, Dharma R. Polisetti, Govindan Subramanian, James C. Quada, Ravindra R. Yarragunta, Robert C. Andrews, Rongyuan Xie
  • Publication number: 20110092553
    Abstract: The present invention provides azole derivatives of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I), and their use in treating human or animal disorders. The compounds of the invention can be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.
    Type: Application
    Filed: November 19, 2010
    Publication date: April 21, 2011
    Applicant: TransTech Pharma, Inc.
    Inventors: Adnan M.M. Mjalli, Dharma R. Polisetti, Govindan Subramanian, James C. Quada, JR., Murty N. Arimilli, Ravindra R. Yarragunta, Robert C. Andrews, Rongyuan Xie
  • Publication number: 20110077399
    Abstract: This invention provides azoles which may be useful as inhibitors of protein tyrosine phosphatases (PTPases). The present invention provides compounds of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds and their use in treating human or animal disorders. The compounds of the invention may be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for the management, treatment, control and adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes, Type II diabetes.
    Type: Application
    Filed: December 1, 2010
    Publication date: March 31, 2011
    Applicant: TRANSTECH PHARMA, INC.
    Inventors: Adnan M. M. Mjalli, Robert C. Andrews, Ravindra R. Yarragunta, Rongyuan Xie, Govindan Subramanian, James C. Quada, JR., Murty N. Arimilli, Dharma R. Polisetti
  • Patent number: 7723369
    Abstract: The present invention provides imidazole derivatives of Formula (I-IV), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I-IV), and their use in treating human or animal disorders. The compounds of the invention inhibit protein tyrosine phosphatase 1B and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.
    Type: Grant
    Filed: January 30, 2007
    Date of Patent: May 25, 2010
    Assignee: TransTech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Dharma R. Polisetti, Govindan Subramanian, James C. Quada, Ravindra R. Yarragunta, Robert C. Andrews, Rongyuan Xie
  • Publication number: 20100113331
    Abstract: The present invention provides imidazole derivatives of Formula (I-IV), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I-IV), and their use in treating human or animal disorders. The compounds of the invention inhibit protein tyrosine phosphatase 1B and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.
    Type: Application
    Filed: January 11, 2010
    Publication date: May 6, 2010
    Applicant: TRANSTECH PHARMA, INC.
    Inventors: ADNAN M. M. MJALLI, DHARMA R. POLISETTI, GOVINDAN SUBRAMANIAN, JAMES C. QUADA, RAVINDRA R. YARRAGUNTA, ROBERT C. ANDREWS, RONGYUAN XIE
  • Patent number: 6933303
    Abstract: This invention provides compounds which are useful as inhibitors of protein tyrosine phosphatases (PTPases). As inhibitors of PTPases, the compounds of the invention are useful for the management, treatment, control and adjunct treatment of diseases mediated by PTPase activity. Such diseases include type I diabetes, type II diabetes, immune dysfunction, AIDS, autoimmunity, glucose intolerance, obesity, cancer, psoriasis, allergic diseases, infectious diseases, inflammatory diseases, diseases involving the modulated synthesis of growth hormone or the modulated synthesis of growth factors or cytokines which affect the production of growth hormone, or Alzheimer's disease.
    Type: Grant
    Filed: October 18, 2002
    Date of Patent: August 23, 2005
    Assignee: TransTech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Robert C. Andrews, Rongyuan Xie, Ravindra R. Yarragunta, Tan Ren
  • Publication number: 20040192743
    Abstract: This invention provides azoles which may be useful as inhibitors of protein tyrosine phosphatases (PTPases). The present invention provides compounds of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds and their use in treating human or animal disorders. The compounds of the invention may be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for the management, treatment, control and adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes, Type II diabetes.
    Type: Application
    Filed: February 12, 2004
    Publication date: September 30, 2004
    Inventors: Adnan M.M. Mjalli, Robert C. Andrews, Ravindra R. Yarragunta, Rongyuan Xie, Govindan Subramanian, James C. Quada, Murty N. Arimilli, Dharma R. Polisetti
  • Publication number: 20040186151
    Abstract: This invention provides azoles which may be useful as inhibitors of protein tyrosine phosphatases (PTPases). The present invention provides compounds of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds and their use in treating human or animal disorders. The compounds of the invention may be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for the management, treatment, control and adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes, Type II diabetes.
    Type: Application
    Filed: February 12, 2004
    Publication date: September 23, 2004
    Inventors: Adnan M.M. Mjalli, Robert C. Andrews, Ravindra R. Yarragunta, Rongyuan Xie, Tan Ren, Govindan Subramanian, James C. Quada
  • Publication number: 20040014778
    Abstract: This invention provides compounds which are useful as inhibitors of protein tyrosine phosphatases (PTPases). As inhibitors of PTPases, the compounds of the invention are useful for the management, treatment, control and adjunct treatment of diseases mediated by PTPase activity. Such diseases include type I diabetes, type II diabetes, immune dysfunction, AIDS, autoimmunity, glucose intolerance, obesity, cancer, psoriasis, allergic diseases, infectious diseases, inflammatory diseases, diseases involving the modulated synthesis of growth hormone or the modulated synthesis of growth factors or cytokines which affect the production of growth hormone, or Alzheimer's disease.
    Type: Application
    Filed: October 18, 2002
    Publication date: January 22, 2004
    Inventors: Adnan M.M. Mjalli, Robert C. Andrews, Rongyuan Xie, Ravindra R. Yarragunta, Tan Ren